KR20220035036A - 엘트롬보팍 투약 요법 - Google Patents

엘트롬보팍 투약 요법 Download PDF

Info

Publication number
KR20220035036A
KR20220035036A KR1020217040929A KR20217040929A KR20220035036A KR 20220035036 A KR20220035036 A KR 20220035036A KR 1020217040929 A KR1020217040929 A KR 1020217040929A KR 20217040929 A KR20217040929 A KR 20217040929A KR 20220035036 A KR20220035036 A KR 20220035036A
Authority
KR
South Korea
Prior art keywords
dose
eltrombopac
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217040929A
Other languages
English (en)
Korean (ko)
Inventor
미오나 스탄코비치
니콜라 쿠퍼
발리 가니마
프란치스코 자야
Original Assignee
노바티스 파마슈티컬즈 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바티스 파마슈티컬즈 코퍼레이션 filed Critical 노바티스 파마슈티컬즈 코퍼레이션
Publication of KR20220035036A publication Critical patent/KR20220035036A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217040929A 2019-05-14 2019-05-14 엘트롬보팍 투약 요법 Ceased KR20220035036A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Publications (1)

Publication Number Publication Date
KR20220035036A true KR20220035036A (ko) 2022-03-21

Family

ID=67211802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040929A Ceased KR20220035036A (ko) 2019-05-14 2019-05-14 엘트롬보팍 투약 요법

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
AU2019445762A1 (en) 2021-12-09
MX2021013971A (es) 2022-04-01
AU2023274065A1 (en) 2023-12-14
JP2022537883A (ja) 2022-08-31
US20220313663A1 (en) 2022-10-06
IL288078A (en) 2025-01-01
CA3140137A1 (en) 2020-11-19
WO2020231407A1 (en) 2020-11-19
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
AU2020201277A1 (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2024530954A5 (cg-RX-API-DMAC7.html)
JP2018505901A (ja) 統合失調症の治療のためのイロペリドン
WO2020231408A1 (en) Eltrombopag dosing regimen
AU2023274065A1 (en) Eltrombopag dosing regimen
US20230167189A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
Ilhem et al. azathioprine for cortico-resistant noninfectious uveitis.
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220510

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220517

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241113

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250602

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D